Is Immunitybio going out of business?

IMMUNITYBIO, INC. (IBRX) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

IMMUNITYBIO, INC. (IBRX) scores 31 out of 100 on fundamentals, Speculative / Volatile, based on SEC filing data.

Leading signal: Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)

Five questions, kept separate

Survival - Critical

1-2 mo of estimated runway from 2026-06-30, based on $75.7M of cash and short-term investments against $533M of annual burn. Adjusted shares outstanding increased 19.3% over the comparison year.

Business quality - Poor

-151.9% operating margin and -321.5% FCF margin produce a poor Business Quality assessment.

Trajectory - Evidence incomplete

Comparable evidence covers 0% of this trajectory model. No comparable revenue evidence.

Valuation - Extreme expectations

-6.2% FCF yield supports an extreme expectations Valuation assessment on the ttm basis.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
• Interest coverage: -4.2x
• Gross margin (health): 99.42%
• Cash Runway (years): 0.14y
• Revenue CAGR (3Y): 678.62%
• Revenue growth YoY: 93.91% (YoY) - Growth from a low base; sustainability uncertain.
• Return on Assets: -157.89%
• Asset Growth Velocity: 56.31% YoY (Aggressive buildout)
• Revenue per Asset Efficiency: 19.26% QoQ (Strong monetization)
• Revenue Quality: High-quality (DSO -43d, Rev +94%)
• FCF margin: -321.52% (Inv. Mode)
• Cash Burn Deceleration: -64.58% QoQ improvement (Worsening)

Read from filings through 2026-08-04.

Price as of 2026-09-07.